Bulls vs. Bears: Can Biogen Keep Booming? Investorplace.com Last week, BIIB announced positive phase 2 clinical trial results for its developmental MS drug daclizumab, noting that it significantly reduced brain lesions in patients with the relapsing-remitting form of the disease. In addition to its MS drugs ... |
